Kiniksa Pharmaceuticals (NASDAQ:KNSA) Given New $35.00 Price Target at Evercore ISI

Kiniksa Pharmaceuticals (NASDAQ:KNSA) had its price objective lifted by Evercore ISI from $30.00 to $35.00 in a research report report published on Wednesday, Benzinga reports. Evercore ISI currently has an outperform rating on the stock.

Several other analysts have also recently commented on KNSA. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Wedbush lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $34.60.

Kiniksa Pharmaceuticals Stock Down 0.5 %

Shares of Kiniksa Pharmaceuticals stock opened at $22.48 on Wednesday. The business has a fifty day simple moving average of $25.40 and a 200-day simple moving average of $22.46. Kiniksa Pharmaceuticals has a 12 month low of $14.12 and a 12 month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business’s quarterly revenue was up 67.4% on a year-over-year basis. During the same period last year, the business earned ($0.20) EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals will post -0.47 EPS for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now directly owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John F. Paolini sold 60,692 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 112,692 shares of company stock valued at $2,950,315. Insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of KNSA. Allspring Global Investments Holdings LLC raised its holdings in Kiniksa Pharmaceuticals by 18.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company’s stock valued at $1,206,000 after buying an additional 9,490 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals by 42.7% in the first quarter. Principal Financial Group Inc. now owns 58,991 shares of the company’s stock worth $1,164,000 after purchasing an additional 17,659 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Kiniksa Pharmaceuticals by 5.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock worth $413,000 after purchasing an additional 1,153 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Kiniksa Pharmaceuticals by 7.8% in the first quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company’s stock worth $530,000 after purchasing an additional 1,940 shares during the period. Finally, Hussman Strategic Advisors Inc. bought a new position in shares of Kiniksa Pharmaceuticals in the first quarter worth about $3,107,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.